

No: /TTr-HĐQT-IMP

Cao Lanh city, , 2020

STATEMENT**Regard to passing audited Financial Statements 2019****Respectfully submit to: The General Meeting of shareholders 2020**

In pursuant to Law on Enterprises No. 68/2014/QH2013;

In pursuant to the Charter of Imexpharm Corporation;

The Board of Directors (BODs) would like to submit to The General Meeting of Shareholders to pass 2019 Financial Statements of Imexpharm Corporation audited by PwC (Vietnam) Co., Ltd.

Audited Financial statement 2019 was disclosed in compliance with the regulation and published in the Company's website: (<http://www.imexpharm.com/doi-tac-nha-dau-tu/imp-bao-cai-chinh-ket-thuc-ngay-31-12-2019/>), including

1. Corporate information
2. Statement by the Board of Management
3. Independent auditor's report
4. Balance sheet (Form B01-DN)
5. Income statement (Form B02-DN)
6. Cash flow statement (Form B03-DN)
7. Notes for the Financial statements (Form B09-DN)

In which:

Some key indicators in audited Financial Statements in 2019

No	Key indicators	Unit	2019	2018
1	Total assets	dong	1,847,174,315,262	1,774,246,689,473
2	Total net revenue and income	dong	1,420,711,494,579	1,207,125,124,703
3	Net revenue	dong	1,402,454,493,864	1,184,817,729,231
4	Profit before tax	dong	202,429,110,631	173,769,437,732
5	Profit after tax	dong	162,386,686,793	138,683,041,628

Respectfully submit to the General Meeting of Shareholders to consider and pass.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN

Mr. Nguyen Quoc Dinh